Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Pharvaris N.V.
  6. News
  7. Summary
    PHVS   NL00150005Y4

PHARVARIS N.V.

(PHVS)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-27 pm EST
9.460 USD   +0.42%
01/11JMP Securities Adjusts Pharvaris' Price Target to $23 From $22, Keeps Market Outperform Rating
MT
01/09Pharvaris Provides Regulatory, Clinical, and Corporate Updates
GL
01/09Pharvaris Provides Regulatory, Clinical, and Corporate Updates
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Pharvaris Shares Soar 79% on Hereditary Angioedema Treatment PHVS416 Data

12/08/2022 | 10:21am EST

By Denny Jacob


Pharvaris NV shares soared 79%, to $4.50, in early trading after the company said data on PHVS416 demonstrated statistically significant results for treatment of hereditary angioedema, a hereditary condition that causes recurrent swelling.

Top-line data from the Phase 2 study of PHVS416 for the prophylactic treatment of hereditary angioedema is expected in the second half of 2023, said Chief Executive Berndt Modig. Data from the proof-of-concept study is expected to inform the design of expected Phase 3 utilizing PHVS719, an investigational treatment currently in Phase 1 clinical development for hereditary angioedema.

The clinical-stage biopharmaceutical company also said it is continuing to work with the U.S. Food and Drug Administration to resolve holds on clinical trials for PHA121, which the company describes as a competitive antagonist of the bradykinin B2 receptor.


Write to Denny Jacob at denny.jacob@wsj.com


(END) Dow Jones Newswires

12-08-22 1020ET

All news about PHARVARIS N.V.
01/11JMP Securities Adjusts Pharvaris' Price Target to $23 From $22, Keeps Market Outperform..
MT
01/09Pharvaris Provides Regulatory, Clinical, and Corporate Updates
GL
01/09Pharvaris Provides Regulatory, Clinical, and Corporate Updates
AQ
2022JMP Securities Adjusts Price Target on Pharvaris to $22 From $18, Maintains Market Outp..
MT
2022Oppenheimer Adjusts Pharvaris Price Target to $24 From $22, Maintains Outperform Rating
MT
2022Top Premarket Decliners
MT
2022Sector Update: Healthcare Stocks Adding to Earlier Gains Near Close Thursd..
MT
2022Top Midday Gainers
MT
2022Sector Update: Health Care Stocks Extending Thursday Advance
MT
2022Sector Update: Health Care
MT
More news
Analyst Recommendations on PHARVARIS N.V.
More recommendations
Financials
Sales 2022 - - -
Net income 2022 -61,7 M -67,0 M -67,0 M
Net cash 2022 162 M 176 M 176 M
P/E ratio 2022 -4,78x
Yield 2022 -
Capitalization 294 M 320 M 320 M
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 56
Free-Float 90,3%
Chart PHARVARIS N.V.
Duration : Period :
Pharvaris N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PHARVARIS N.V.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 8,71 €
Average target price 15,78 €
Spread / Average Target 81,1%
EPS Revisions
Managers and Directors
Berndt A. E. Modig Chief Executive Officer & Executive Director
Anna Nijdam Principal Accounting Officer & Head-Finance
David P. Meeker Chairman
Jochen Knolle Chief Operating & Scientific Officer
Peng Lu Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PHARVARIS N.V.-15.91%320
MODERNA, INC.7.58%72 745
LONZA GROUP AG17.24%42 787
IQVIA HOLDINGS INC.12.00%42 622
ALNYLAM PHARMACEUTICALS, INC.-2.55%28 465
SEAGEN INC.9.46%26 117